Author

I. Kroidl

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

C. Geldmacher· 2 shared M. Hoelscher· 2 shared A. Janjic· 1 shared A. Leunig· 1 shared A. Linder· 1 shared A. Wieser· 1 shared C. Drosten· 1 shared C. Gold· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. Geldmacher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

S. M. Reincke, M. Yuan, H.-C. Kornau, V. M. Corman, S. van Hoof, E. Sanchez-Sendin, M. Ramberger, W. Yu, Y. Hua, H. Tien, M. L. Schmidt, T. Schwarz, L. M. Jeworowski, S. E. Brandl, H. Foverskov Rasmussen, , J. Kreye

SARS-CoV-2 Beta variant infection generates lineage-specific antibodies and cross-reactive antibodies with neutralizing activity against wild-type and other variants.

bioRxiv · Sep 30, 2021Immunology

Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection

K. Pekayvaz, A. Leunig, R. Kaiser, S. Brambs, M. Joppich, A. Janjic, O. Popp, V. Polewka, L. E. Wange, C. Gold, M. Kirchner, M. Muenchhoff, J. C. Hellmuth, C. Scherer, T. Eser, , L. Nicolai

This study identifies an early interferon-stimulated gene (ISG) upregulation as a protective immune signature in non-pneumonic SARS-CoV-2 infection, preventing progression to pneumonia.

bioRxiv · Feb 3, 2021Immunology